Session 8: Investigating the Path from PI3K to Protein Synthesis to Tailor Prostate Cancer Therapy
29th Annual PCF Scientific Retreat: October 28, 2022 | 5:00 PM – 6:00 PM
Moderator: Daniela Brina, PhD
Institute of Oncology Research, Switzerland
Therapeutic Targeting of the Translational Machinery Blocks MDSCs and Enhances Anti-Tumor Immunity in Prostate Cancer
Daniela Brina, PhD
Institute of Oncology Research, Switzerland
Defining the Therapeutic Selective Dependencies for Distinct Subtypes of PI3K Pathway-Altered Prostate Cancers
Brett Carver, MD
Memorial Sloan Kettering Cancer Center
The Androgen Receptor Regulates a Druggable Translational Regulon in Advanced Prostate Cancer
Andrew Hsieh, MD
Fred Hutchison Cancer Center